VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
0.1271
-0.0108 (-7.83%)
At close: Nov 13, 2026, 4:00 PM EST
0.1261
-0.0010 (-0.79%)
After-hours: Nov 13, 2026, 7:46 PM EST
VivoSim Labs Employees
VivoSim Labs had 15 employees as of June 30, 2026. The number of employees did not change since the number was last reported on March 31, 2026. That makes VivoSim Labs the 39,334th largest employer in the world and 5,762nd in the United States.
Employees
15
Change
n/a
Growth
n/a
Revenue / Employee
$9,000
Profits / Employee
-$684,533
Market Cap
2.11M
Employees Chart
| Date | Employees | Change | Growth | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 15 | 0 | - | 15 | 0 |
| Mar 31, 2026 | 15 | 2 | 15.38% | 9 | 6 |
| Mar 31, 2025 | 13 | -7 | -35.00% | 5 | 8 |
| Mar 31, 2024 | 20 | -4 | -16.67% | 12 | 8 |
| Mar 31, 2023 | 24 | 6 | 33.33% | 15 | 9 |
| Mar 31, 2022 | 18 | 9 | 100.00% | 9 | 9 |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| Calidi Biotherapeutics | 29 |
| Curis | 24 |
| BioRestorative Therapies | 14 |
| Genprex | 13 |
| Revelation Biosciences | 9 |
| Dermata Therapeutics | 9 |
| Eocene | 6 |
VIVS News
- 3 days ago - VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting - GlobeNewsWire
- 10 days ago - VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test - GlobeNewsWire
- 23 days ago - VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling - GlobeNewsWire
- 5 weeks ago - VivoSim celebrates updated FDA regulations in non-animal testing methods - TheFly
- 5 weeks ago - VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods - GlobeNewsWire
- 1 month ago - VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs - GlobeNewsWire
- 2 months ago - VivoSim Labs to Add Rat Liver Model to NAMkind Platform - GlobeNewsWire
- 3 months ago - VivoSim regains compliance with Nasdaq - TheFly